| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/27/2001 | US6194392 Administering to a patient suffering from swelling associated with brain tumours involving tissue of the group consisting of underperfused tissue and pathological tissue an antiswelling agent and a hyaluronic acid to aid penetration |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194020 Conserving procyanidins(catechins); candy |
| 02/27/2001 | US6194004 Dry mix formulation for bisphosphonic acids |
| 02/27/2001 | US6194001 Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient |
| 02/27/2001 | US6193998 Method for producing liposomes with increased percent of compound encapsulated |
| 02/27/2001 | US6193997 Proteinic drug delivery system using membrane mimetics |
| 02/27/2001 | US6193996 Device for the transdermal delivery of diclofenac |
| 02/27/2001 | US6193994 Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
| 02/27/2001 | US6193993 Suppository containing an antidementia medicament |
| 02/27/2001 | US6193992 Administering apomorphine to increase intraclitoral blood flow and vaginal wall blood flow on stimulation but less than amount that induces nausea to treat sexual dysfunction |
| 02/27/2001 | US6193991 Nontoxic; controlled release of drugs |
| 02/27/2001 | US6193989 Administering drug comprising ivermectin, benzyl alcohol, polyvinylpyrrolidone, n-methyl-2-pyrrolidone, and glycerin by injecting animal to treat parasite infection |
| 02/27/2001 | US6193985 Tocopherol compositions for delivery of biologically active agents |
| 02/27/2001 | US6193982 Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
| 02/27/2001 | US6193970 Potentiating local inflammatory or immune response to administration of tumor antigen in mammalian subject by administering tumor antigen in form of tumor cells, or subcellular antigenic material and cytokine or cytokines |
| 02/27/2001 | US6193962 Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resin |
| 02/27/2001 | US6193951 Microparticles useful as ultrasonic contrast agents |
| 02/27/2001 | CA2168249C Psoriasis treatment |
| 02/22/2001 | WO2001012832A1 Process for producing lycopen |
| 02/22/2001 | WO2001012810A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 02/22/2001 | WO2001012797A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 02/22/2001 | WO2001012718A1 Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof |
| 02/22/2001 | WO2001012653A1 Stabilisation of freeze-dried cake |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012579A2 New stilbenes with vascular damaging activity |
| 02/22/2001 | WO2001012550A1 POLYTYPE Mg-Al HYDROTALCITE |
| 02/22/2001 | WO2001012247A1 Tissue augmentation material and method |
| 02/22/2001 | WO2001012235A2 Targeted artificial gene delivery |
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012232A2 Process to make a sustained release formulation |
| 02/22/2001 | WO2001012231A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 02/22/2001 | WO2001012230A1 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers |
| 02/22/2001 | WO2001012229A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | WO2001012217A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 02/22/2001 | WO2001012214A2 MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) |
| 02/22/2001 | WO2001012200A1 An oral composition comprising coenzyme a for treating hyperlipemia, the preparation method and the use thereof |
| 02/22/2001 | WO2001012193A1 Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 02/22/2001 | WO2001012181A1 Improved topical medicaments and methods for photodynamic treatment of disease |
| 02/22/2001 | WO2001012177A1 Formation of nanometer-scale structures |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012170A2 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 02/22/2001 | WO2001012164A1 Oral form of administration containing probiotic micro-organisms |
| 02/22/2001 | WO2001012162A1 Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof |
| 02/22/2001 | WO2001012161A1 Rapidly dissolving dosage form and process for making same |
| 02/22/2001 | WO2001012160A1 Microparticles for pulmonary administration |
| 02/22/2001 | WO2001012159A2 Artificial tear replacement solution |
| 02/22/2001 | WO2001012156A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2001012154A2 Targeted lipid particles |
| 02/22/2001 | WO2001011964A1 Ectoparasiticidal aqueous suspension formulations of spinosyns |
| 02/22/2001 | WO2001011960A1 A mucosal specific gene delivery system based on modified bacterial exotoxin |
| 02/22/2001 | WO2000078941A3 Methods and products for manipulating uncoupling protein expression |
| 02/22/2001 | WO2000074677A3 Improved pharmaceutical formulations |
| 02/22/2001 | WO2000069470A3 Improved cellular uptake of bioactive agents |
| 02/22/2001 | WO2000063385A3 Nucleic acid immunization |
| 02/22/2001 | WO2000057853A3 Pharmaceutical composition containing an extrusion additive |
| 02/22/2001 | WO2000023065A8 Storable active substance concentrate with formoterol |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | WO1999063992A8 Novel calcium channel drugs and uses |
| 02/22/2001 | DE19939578A1 New nucleic acid encoding hemocyanin, useful for gene therapy of tumors and for recombinant production of fusion proteins for vaccination |
| 02/22/2001 | DE19939565A1 Branched unsaturated fatty alcohol sulfates of improved stability to auto-oxidation are useful in e.g. detergents, cosmetics and pharmaceutical preparations and are prepared from dimerized fatty acids |
| 02/22/2001 | DE19939538A1 Branched unsaturated fatty alcohol polyglycol ethers of improved stability to auto-oxidation are useful in e.g. detergents, cosmetics and pharmaceutical preparations and are prepared from dimerized fatty acids |
| 02/22/2001 | DE19939537A1 Branched unsaturated fatty alcohol ether sulfates of improved stability to auto-oxidation are useful in e.g. detergents, cosmetics and pharmaceutical preparations and are prepared from dimerized fatty acids |
| 02/22/2001 | DE19938756A1 Dünnflüssige kosmetische oder dermatologische Zubereitungen vom Typ Öl-in-Wasser Low-viscosity cosmetic or dermatological preparations of the oil-in-water |
| 02/22/2001 | DE19938668A1 Tränenersatzmittel Artificial tears |
| 02/22/2001 | DE19937361A1 Orale Darreichungsform The oral dosage form |
| 02/22/2001 | CA2689735A1 Compositions comprising modafinil for treatment of fatigue associated with multiple sclerosis |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2381287A1 Polytype mg-ai hydrotalcite |
| 02/22/2001 | CA2380932A1 Tissue augmentation material and methods |
| 02/22/2001 | CA2380892A1 Formation of nanometer-scale structures |
| 02/22/2001 | CA2380883A1 Microparticles for pulmonary administration |
| 02/22/2001 | CA2380653A1 Mycophenolate mofetil in association with peg-ifn-.alpha. |
| 02/22/2001 | CA2380643A1 Topical organic ectoparasiticidal formulations |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380517A1 Targeted artificial gene delivery |
| 02/22/2001 | CA2380449A1 Rapidly dissolving dosage form and process for making same |
| 02/22/2001 | CA2380432A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | CA2379940A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 02/22/2001 | CA2379544A1 New stilbenes with vascular damaging activity |
| 02/22/2001 | CA2379431A1 Targeted lipid particles |
| 02/22/2001 | CA2379196A1 Rotavirus vaccine formulations |
| 02/22/2001 | CA2378708A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 02/22/2001 | CA2377415A1 An oral administration form |
| 02/21/2001 | EP1077073A1 Resorbable copolylactides and their use |
| 02/21/2001 | EP1077070A2 Oral drug delivery compositions |
| 02/21/2001 | EP1077065A1 Regulated release preparations |
| 02/21/2001 | EP1077064A1 Use of peroxidised lipids as lipidic film forming agents on the skin |
| 02/21/2001 | EP1077062A2 Fluid cosmetic or dermatological compositions of the oil-in-water type |
| 02/21/2001 | EP1076671A1 Non cross-linked block polyetherester, preparation and uses |
| 02/21/2001 | EP1076662A2 Polyepitope carrier protein |
| 02/21/2001 | EP1076555A1 Pectic preparations used as medicine carrier |
| 02/21/2001 | EP1076547A2 Derivatives of arabinogalactan and compositions including the same |
| 02/21/2001 | EP0988029A4 Device and methods for wound treatment |
| 02/21/2001 | EP0809628B1 Amphiphilic compounds with at least two hydrophilic and at least two hydrophobic groups based on dicarboxylic acid diamides |
| 02/21/2001 | EP0784683B1 Tie-2 ligands, methods of making and uses thereof |
| 02/21/2001 | CN1284877A Gastroprotected omerprazole microgranules, method for obtaining same and pharmaceutical preparations |
| 02/21/2001 | CN1284876A Insoluble compositions for controlling blood glucose |